Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (64)	12/6/2001 8:27:12 PM
From: opalapril	Respond to of 75

Actually, I think it is more than coincidence. Didn't the same thing happen during economic recesssions in ''83 & '92? Then, it was pharmas doing the gobbling up. Now it's other biotechs. But the principle is the same: Big fish eat little fish, especially when the latter look especially cheap as well as delicious.

To: Edscharp who wrote (64)	12/7/2001 10:56:48 AM
From: Edscharp	Respond to of 75

Opal, Good point. Nonetheless, I think I'm going to stick to my strategy of investing in biotechs that have very late stage products with large potential markets. I also like biotechs that are based upon "concepts". For instance Onyx Pharmaceuticals has a late stage P3 trial utilizing their virus technology and the same for Isis Pharmaceuticals with their anti-sense technology. The point here is that if either of these companies complete successful trials, not only is there the obvious benefit of an approved drug, but a vinidication of the technology behind the success which could lead to scores of other medications. Of course, there is always a risk. Your favorite and mine, Xoma, comes to mind. I thought Neuprex would be the wonder drug of the new millenia. LOL! Regards, Ed